Dynavax Expects to Resume Heplisav Testing

Dynavax Technologies Corp. said it believes it will be able to resume clinical testing of its hepatitis B vaccine in 2009. Tests of the drug, Heplisav, were stopped by the Food and Drug Administration in April because of "a serious adverse event" in a person who received the vaccine during safety and efficacy testing.
East Bay Business Times